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Actomyosin contractilityCleft formation is the initial step in submandibular salivary gland (SMG) branching morphogenesis, and
may result from localized actomyosin-mediated cellular contraction. Since ROCK regulates cytoskeletal
contraction, we investigated the effects of ROCK inhibition on mouse SMG ex vivo organ cultures.
Pharmacological inhibitors of ROCK, isoform-speciﬁc ROCK I but not ROCK II siRNAs, as well as inhibitors of
myosin II activity stalled clefts at initiation. This ﬁnding implies the existence of a mechanochemical
checkpoint regulating the transition of initiated clefts into progression-competent clefts. Downstream of
the checkpoint, clefts are rendered competent through localized assembly of ﬁbronectin promoted by
ROCK I/myosin II. Cleft progression is primarily mediated by ROCK I/myosin II-stimulated cell proliferation
with a contribution from cellular contraction. Furthermore, we demonstrate that FN assembly itself
promotes epithelial proliferation and cleft progression in a ROCK-dependent manner. ROCK also stimulates
a proliferation-independent negative feedback loop to prevent further cleft initiations. These results reveal
that cleft initiation and progression are two physically and biochemically distinct processes.
© 2009 Elsevier Inc. All rights reserved.Introduction
Mechanical forces play a pervasive role in regulating morphoge-
netic changes during embryonic organ development. Cells sense and
respond to changes in their microenvironment by contracting and
pulling on the extracellular matrix (ECM) and on neighboring cells.
Inside the cell, contractile activity is generated by the interaction of
activated non-muscle myosin II with actin. This cellular contractility
has been implicated in cellular rearrangements and migration (Keller
et al., 2003; Kiehart et al., 2000; Xu et al., 2008), proliferation (Huang
et al., 1998), and differentiation (McBeath et al., 2004). However, the
molecular mechanisms by which cells coordinate forces with cellular
responses resulting in morphogenesis remain unclear.
Branching morphogenesis is a developmental mechanism utilized
by many organs, including the salivary gland, lung, kidney, and
mammary gland, to increase the epithelial surface area for secretion
or absorption (Hogan, 1999). The embryonic submandibular salivary
gland (SMG) is a classic model for studying tissue morphogenesis in
three dimensions ex vivo (Grobstein, 1953). On embryonic day 12
(E12), the ﬁrst round of branching begins as multiple clefts, or
indentations, are formed in the basement membrane covering the
surface of the epithelium. These clefts then extend, or progress,Y, Department of Biological
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multiple times to generate the complex, arborized adult structure.
Whilemany growth regulatory pathways are implicated in the control
of branching (Patel et al., 2006; Tucker, 2007), the nature of the
physical changes that occur during these morphogenetic events is not
understood.
Several hypotheses have been proposed to explain cleft formation.
Localized cell proliferation has long been known to play a critical role
in branching morphogenesis (Bernﬁeld et al., 1972; Nogawa et al.,
1998), although a direct requirement for proliferation in SMG cleft
formation was ruled out in studies using proliferation inhibitors since
clefts were still observed to initiate under such conditions (Nakanishi
et al., 1987). However, these studies failed to distinguish between
cleft initiation and progression, and did not investigate whether once
initiated, if such clefts continued to progress in the absence of
proliferation. Basement membrane dynamics have also been identi-
ﬁed as a possible driving force for SMG cleft formation. Classic studies
demonstrated that collagen III preferentially accumulates at sites of
cleft initiation (Fukuda et al., 1988; Nakanishi et al., 1988), and more
recently, the ECM protein ﬁbronectin (FN) has been identiﬁed as a
putative cleft initiator molecule (Sakai et al., 2003). siRNA knockdown
of FN prevents cleft formation in E12 SMGs, while the addition of
exogenous FN promotes epithelial cleft formation and leads to
decreased E-cadherin-mediated cell–cell adhesions. However, the
relationship between FN and proliferation was not examined in this
study, nor was an upstream signal identiﬁed. Finally, a requirement
for the actin cytoskeleton was identiﬁed in early studies. SMGs
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polymerization, fail to form clefts (Spooner and Wessells, 1972), in
support of a hypothesis that actomyosin contractility is required for
branching morphogenesis. Mathematical modeling has also implicat-
ed contractile events occurring within the mesenchyme as a key
contributor to this process, and suggests that the resulting traction
forces produced by such mesenchymal contraction may help drive
cleft formation by deforming the epithelial surface (Nakanishi et al.,
1986; Wan et al., 2008).
Actin rearrangements and cellular contractility can be controlled
by Rho-associated coiled-coil containing kinase (ROCK). ROCK
activates myosin light chain 2 (MLC2) through phosphorylation of
Ser19 (Amano et al., 1996; Totsukawa et al., 2000), which is required
for its interaction with actin (Landsverk and Epstein, 2005).
Furthermore, signaling through ROCK and the resulting cytoskeletal
contraction regulates FN assembly in ﬁbroblasts, primarily through
the unfolding of cell surface-bound FN to expose a cryptic self-
assembly site (Baneyx et al., 2002; Yoneda et al., 2007; Zhong et al.,
1998).
ROCK activity is implicated in the development of other branching
organs. In the embryonic lung, inhibition of ROCK reduces branching
morphogenesis, and results in the loss of localized differentials in
basement membrane thickness and cell proliferation (Moore et al.,
2005). A role for FN in this process was not investigated, despite the
fact that FN is also required for lung branching morphogenesis (De
Langhe et al., 2005; Sakai et al., 2003). Furthermore, a direct link
between basement membrane remodeling and localized proliferation
was not established. In the developing kidney, ROCK inhibition was
reported to promote ureteric bud branching, despite downstream
alterations to the actin cytoskeletal structure (Meyer et al., 2006;
Michael et al., 2005). Thus, the molecular functions of ROCK in
branching morphogenesis have not been clearly deﬁned, and
differences between organs are apparent.
In the current study using the developing embryonic mouse
submandibular salivary gland as a model branching organ, we report
the existence of a mechanochemical checkpoint regulating the
transition of clefts to a stabilized state competent to undergo
progression. We report that inhibition of ROCK I or non-muscle
myosin II activity prevents passage through this checkpoint, and stalls
clefts at the initiation stage. In the presence of ROCK/myosin II
inhibition, failure of clefts to progress is due to disrupted FN assembly
in the basement membrane and a lack of proliferation by basal
epithelial cells. Furthermore, we demonstrate that FN assembly itself
promotes epithelial proliferation and cleft progression in a ROCK-
dependent manner. Interestingly, we also detect an increased number
of initiated clefts that fail to progress in the presence of ROCK I/
myosin II inhibitors, indicating the existence of a negative feedback
loop that temporarily prevents additional cleft initiations locally in a
proliferation-independent manner. These studies provide mechanis-
tic evidence that cleft initiation and progression are two distinct
events during SMG branching morphogenesis.
Materials and methods
Submandibular salivary gland ex vivo organ culture and inhibitor assays
Mouse SMGs were dissected from timed-pregnant female mice
(strain CD-1, Charles River Laboratories) at either embryonic day 12
(E12, 1 bud) or E13 (4–5 buds), with the day of plug discovery
designated as E0, following protocols approved by the University at
Albany IACUC committee. SMGs were microdissected from mandible
slices and cultured as previously described (Rebustini and Hoffman,
2009; Sakai and Onodera, 2008). Brieﬂy, mandible slices were
removed from embryos with a sterile scalpel and, from these, SMGs
were microdissected using sterile forceps under a dissecting micro-
scope (SMZ645, Nikon). The SMGs were cultured on 13 mm, 0.1 μmNuclepore Track-Etch membrane ﬁlters (Whatman) ﬂoating on
200 μL of 1:1 DMEM/Ham's F12 Medium (F12) lacking phenol red
(Invitrogen) in glass-bottom 50 mm microwell dishes (MatTek
Corporation). The medium was supplemented with 50 μg/mL
transferrin, 150 μg/mL L-ascorbic acid, 100 U/mL penicillin, and
100 μg/mL streptomycin, to make complete DMEM/F12 medium.
For experiments using SMG epithelial rudiments, dissected SMGs
were incubated in 1.6 U/mL dispase (Roche) prepared in HBSS
(Invitrogen) for 25 min at 37 °C. The dispase was neutralized with 5%
BSA in DMEM/F12, and the mesenchyme physically separated from
the epithelium with ﬁne forceps. SMG epithelial rudiments were
cultured in a ﬁnal concentration of 6 mg/mL Matrigel (BD
Biosciences) diluted in DMEM/F12 containing 20 ng/mL EGF and
200 ng/mL FGF7 (R&D Systems). Five intact SMGs or three epithelial
rudiments were used for each experimental condition and all
experiments were repeated at least three times.
Pharmacological inhibitors (Calbiochem) were resuspended in
DMEM/F12 or DMSO vehicle, as recommended by the manufacturer:
Y27632 (688000), H-1152 (555550), (−)-blebbistatin (203391),
(+)-blebbistatin (negative control for (−)-Blebbistatin, 203392),
and hydroxyurea (400046). Inhibitor-containingmedia were replaced
every 24 h. Brightﬁeld images were acquired on a Nikon Eclipse TS100
microscope equipped with a Canon EOS 450D digital camera at either
4× (Plan 4×/0.10 NA), 10× (10×Ph1 ADL/0.25 NA), or 20× (LWD 20×
Ph1 ADL/0.40 NA) magniﬁcation.
Morphometric analysis was performed using MetaMorph™ (Ver-
sion 6.1, MDS Analytical Technologies), as described previously
(Larsen et al., 2003). Fold change was calculated by normalizing to
the number of buds or clefts present at the initial time point (2 h) and
displayed using Prism (GraphPad, Version 5.01). Thickness measure-
ments were generated from glands treated for 24 h, ﬁxed, and stained
with rhodamine phalloidin (Invitrogen, 1:350). Thickness was
calculated from Z-stacks acquired using a confocal microscope (LSM
510 Meta with Argon, HeNe1, and HeNe2 lasers, Carl Zeiss). For SMG
diameter measurements, brightﬁeld tiff ﬁles were imported into
MetaMorph, and the diameter was measured using the calibrated line
tool.
siRNA knockdown of ROCK I, ROCK II, and FN
The following pre-validated duplexed siRNAs (Validated Silencer
Select) were obtained from Applied Biosystems: ROCK I, s73018, and
s73019; ROCK II, s73021, and s73022; FN1, s66182, and s66183;
Negative Control siRNA #1; Negative Control siRNA #2; and Cy3-
conjugated Negative Control siRNA #1. SMGs were transfected with
100–500 nM siRNA using RNAiFect (Qiagen) according to the
manufacturer's protocol, and cultured for 24–48 h. Each experiment
was repeated 2–4 times for each siRNA with 5 SMGs per group.
SCA-9 cell culture and live FN assays
Themouse SMG-derived epithelial cell line, SCA-9, developed from
an induced tumor derived from adult mouse submandibular gland,
was maintained as previously described (Barka et al., 2005, 1980).
SCA-9 cells were cultured overnight to 70% conﬂuence, washed with
1× PBS, and grown for 18 h in serum-free DMEM containing vehicle
control or inhibitors. To detect ﬁbrillar FN, puriﬁed human plasma FN
(Akiyama, 1999) that was labeled with Alexa647 (Larsen et al., 2006)
was added to SCA-9 cell cultures at 0.02 μg/μL in serum-free media.
Cells were imaged by time-lapse microscopy for 18 h or immunos-
tained with L8 monoclonal (Chernousov et al., 1987) to label
stretched FN and an anti-FN rabbit polyclonal antibody to label total
FN. Imunocytochemistry was performed as described previously
(Cukierman et al., 2001), and cells were imaged on an inverted
ﬂuorescence microscope (Cell Observer Z1, Carl Zeiss) with a CCD
camera (Axiocam MRm, Carl Zeiss) at 63× magniﬁcation (Plan-
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extractions for ﬁbrillar ﬁbronectin were performed as reported
previously (McKeown-Longo and Mosher, 1983), except that cells
were collected into 2% DOC extraction buffer with a mini protease
inhibitor tablet (Roche) and analyzed by Western analysis, as
described.
Time-lapse microscopy
Time-lapse microscopy was performed essentially as previously
described (Larsen et al., 2006, 2003), except that a Cell Observer Z1
(Carl Zeiss) ﬁtted with an environmental chamber (XL-S1, Carl Zeiss)
and calibrated for 5% CO2 at the center of the stage was used to
capture images. Phase contrast images were captured every 10 min
for 20 h using AxioVision software (Release 4.7.1, Carl Zeiss) at 5×
(Plan Neo, NA 0.16), 10× (Plan Neo, 0.3 NA), or 20× (Plan Neo, NA 0.5)
magniﬁcation. Images were automatically registered in AxioVision
and then adjusted for brightness and contrast and converted into
movies (AVI format/Cinepak codec) in MetaMorph. For cleft mea-
surements, SMGs were imaged for 12 h and images imported into
MetaVue (Version 6.2r6, Molecular Devices). Stacks were adjusted for
brightness and contrast, and equally cropped to assemble movies and
montages. Morphometric measurements were acquired with the line
tool from two clefts each from three SMGs using the top edge of the
cropped box as a reference. See Fig. S4A for a detailed description of
the measurements and calculations of elongation index (EI), contrac-
tion index (CI), and progression index (PI).
Whole-mount immunocytochemistry
Immunostainingwas performed essentially as described (Larsen et
al., 2003) with all antibody incubations performed overnight at 4 °C.
SMGs were washed 4× for 10 min in 1× PBS-T after each antibody
incubation step, and mounted on glass coverslips with Secure-seal
imaging spacers (Grace Bio-Labs) in 40 μL BioMeda™ Gel-Mount
(Electron Microscopy Sciences) containing 1 mg/mL P-phenylene-
diamine (PPD) antifade reagent. SMGs were imaged on a Zeiss
LSM510 confocal microscope at 10× (Fluar 10×/0.50 NA), 20× (Plan
Apo/0.75 NA), or 63× (Plan Apo/1.4 NA) magniﬁcation.
Antibodies used and their dilutions from stock are as follows: E-
cadherin (Clone 36, BD Biosciences, 1:250), ROCK I (Clone EP786Y,
Abcam, 1:250), ROCK II (H-85, Santa Cruz Biotechnology, 1:50),
pMLC2 (Ser 19) (#3671, Cell Signaling Technology, 1:50), Myosin IIb
(#3404, Cell Signaling Technology, 1:100), Na+/K+ ATPase (EP1845Y,
Epitomics, 1:100), BrdU (Roche, 1:10), and the heparan sulfate
proteoglycan, perlecan (clone A7L6, Chemicon, 1:100). Anti-ﬁbronec-
tin rabbit polyclonal antibody R5836 (1:25) and L8 monoclonal
antibody (25 μg/mL) were generously provided by Drs. Kenneth
Yamada and Michael Chernousov, respectively. SYBR Green I
(Invitrogen, 1:100,000) and Alexa Fluor546 Phalloidin (Invitrogen,
1:350) were also used. Cyanine dye-conjugated AfﬁniPure F(ab′)2
fragments were used as secondary antibodies (Jackson ImmunoR-
esearch Laboratories, 1:50).
Western analysis
Protein assays and Western blot analysis were performed
essentially as previously described (Larsen et al., 2003) except that
5–10 μg of protein was loaded per well on a 1-mm NuPAGER 4–12%
Bis-Tris Gel, electrophoresed, and transferred to a PVDF membrane
using the Invitrogen XCell Surelock™ system (Invitrogen). Chemilu-
minescent blots were imaged using a BioRad ChemiDOC XRS™
(BioRad) or X-ray ﬁlm (ECL Hyperﬁlm) and bands quantiﬁed using
Quantity One (Version 4.6.1, BioRad) with normalization to GAPDH or
MLC2 (for pMLC2). Each experiment was repeated three times, but a
single blot and quantiﬁcation of that blot are shown in each ﬁgure.Antibodies used and their dilutions are as follows: ROCK I (EP786Y,
Abcam, 1:500), ROCK II (H-85, Santa Cruz, 1:200), E-cadherin (Clone
36, BD Biosciences, 1:5,000), Vimentin (Clone 13.2, Sigma, 1:10,000),
β-Actin (Clone AC-74, Sigma, 1:10,000), Phospho-Myosin Light Chain
2 (Ser19) (Cell Signaling, 1:1000), Myosin Light Chain 2 (Cell
Signaling, 1:1,000), anti-FN rabbit polyclonal antibody (Ken Yamada,
1:1,000), and GAPDH (Fitzgerald, 1:10,000).
Proliferation and apoptosis assays
For cell proliferation studies, intact E13 SMGs were cultured for 24
h in the presence of inhibitor, vehicle control, FN siRNA, or exogenous
human plasma FN and pulsed for 2 h with BrdU using a BrdU Labeling
and Detection Kit (Roche), as described previously (Steinberg et al.,
2005), with the following modiﬁcations. Following the anti-BrdU
antibody (1:10) incubation step, SMGs were blocked and immunos-
tained as described above using an antibody recognizing Na+/K+
ATPase (1:100) to detect primarily the epithelium, anti-FN antibody
(1:25) to assess FN knockdown, and SYBR green to counterstain total
nuclei. The BrdU/SYBR green ratio was calculated from confocal stacks
spanning the thickness of the entire SMG and graphed in Prism.
Apoptosis was compared by TUNEL staining with an In Situ Cell
Death Detection Kit (Roche) according to the manufacturer's instruc-
tions but with an additional immunostaining step added to detect E-
cadherin and SYBR Green to label total nuclei. TUNEL-positive nuclei
were quantiﬁed inMetaMorph as the ratio of TUNEL/SYBR green from
confocal stacks and graphed in Prism.
Statistical analysis
For all experiments, one-way analysis of variance (ANOVA) was
performed with a Bonferroni post-test, except when otherwise
indicated, using Prism. All graphs show one representative experi-
ment of at least three.
Results
Pharmacological inhibitors of ROCK stall SMG branching morphogenesis
at the cleft initiation stage and allow additional cleft initiations
To determine if ROCK-mediated signaling is a critical component
of cleft formation during SMG branching morphogenesis, we treated
embryonic day 13 (E13) SMGs with increasing concentrations of
Y27632 and H-1152, two structurally distinct pharmacological
inhibitors that block the catalytic site of both ROCK isoforms, ROCK I
and II (Ikenoya et al., 2002; Uehata et al., 1997). Control SMGs
cultured for 24 h underwent several rounds of branching, while SMGs
treated with Y27632 or H-1152 exhibited a morphology typiﬁed by
larger, less-branched buds, relative to vehicle control. Morphometric
analysis revealed a dose-dependent decrease in the number of
completed epithelial buds (Fig. 1A).
Since the larger-sized buds in ROCK-inhibited SMGs could be
explained by decreased clefting, we investigated how ROCK signaling
affects SMG cleft formation by time-lapse imaging of intact E13 SMGs
(Movie S1). When SMGs were cultured with either ROCK inhibitor,
multiple clefts initiated at the surface of the large buds, but did not
continue to lengthen, or progress, as they did in vehicle control-
treated glands (white arrows, Fig. 1B). In fact, morphometric analysis
revealed a dose-dependent increase in the number of initiated, but
not elongated, clefts in the presence of both ROCK inhibitors (Fig. 1B).
The increased number of initiated clefts observed upon ROCK
inhibition suggests that ROCK activity is not required for cleft
initiation itself. However, because cleft formation begins at E12, and
we added the inhibitors on E13, it is possible that clefts had all ready
initiated on E12 when ROCK activity was not perturbed. To directly
rule out this possibility, we cultured E12 SMGs in the presence of
Fig. 1. Pharmacological inhibition of ROCK blocks SMG branching morphogenesis in organ culture. (A) Images of live E13 SMGs treated with increasing concentrations of Y27632 and
H-1152 for 24 h exhibit decreased branching relative to vehicle control (see also Movie S1). Quantiﬁcation of the number of buds after 24 h revealed a dose-dependent inhibition of
branching in the presence of both ROCK inhibitors. (B) E13 SMGs treated for 24 h with 140 μM Y27632 or 2 μM H-1152 exhibit an increased number of initiated, but not elongated,
clefts on the surface of epithelial buds relative to vehicle control (compare white arrows). Quantiﬁcation revealed a dose-dependent increase in such immature clefts with both
Y27632 and H-1152. (C) Branching morphogenesis of E12 SMGs treated with either 140 μM Y27632 or 2 μM H-1152 for 24 h is also inhibited at the cleft initiation stage. ROCK
inhibition results in an increased number of initiated, but not elongated clefts (compare white arrows). (D) E13 SMG epithelial rudiments cultured for 24 h with 140 μM Y27632 or
2 μM H-1152 also show multiple initiated immature clefts (see also Movie S1). Quantiﬁcation reveals both a dose-dependent decrease in completed buds and an increase in small
initiated clefts. ANOVA, ⁎pb0.05, ⁎⁎pb0.01, N=5. Scale bars, 250 μm (A, C, and D) and 50 μm (B and C).
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morphometric analysis on the cleft regions. E12 SMGs treated with
both ROCK inhibitors likewise showed a signiﬁcant inhibition of
branching morphogenesis (Fig. 1C), thus indicating that ROCK
signaling is also involved in the initial round of branching.
Furthermore, as in E13 SMGs, there was an increased number of
small initiated, but not elongated, clefts in the surface of the
epithelium in the presence of the ROCK inhibitors (white arrows,
Fig. 1C). Taken together, these results conclusively demonstrate that
ROCK signaling is not required for cleft initiation, since clefts still
initiate under conditions of ROCK inhibition at E12, prior to the ﬁrst
round of cleft formation.
In order to ensure that Y27632 and H-1152 were not toxic, we
performed wash-out experiments in which both E12 and E13 SMGsshowed signiﬁcant recovery 48 h after the wash-out (Fig. S1A and B).
To conﬁrm that the inhibitors did not induce apoptosis, we performed
TUNEL assays after 24 h of culture, and observed no signiﬁcant
differences in the number of apoptotic nuclei for vehicle control-
treated and ROCK-inhibited SMGs (Fig. S1C). Taken together, these
data indicate that ROCK inhibition with two structurally distinct
pharmacological inhibitors blocks SMG branching morphogenesis at
the cleft initiation stage both during the initial and later stages of
branching in a manner that is non-toxic to developing SMGs.
To determine if ROCK signaling is active within the epithelium
itself, we cultured E13 epithelial rudiments in the absence of
mesenchyme (Morita and Nogawa, 1999). As with the intact SMGs,
ROCK inhibitionwith Y27632 and H-1152 resulted in a decrease in the
number of fully completed buds and an increase in the number of
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data not shown). Time-lapse microscopy further conﬁrmed these
observations (Movie S1). These results demonstrate that ROCK
signaling within SMG epithelial cells is an important determinant of
branching morphogenesis and that inhibition of such signaling blocks
cleft progression, but facilitates the initiation of additional clefts at the
surface of epithelial buds even in the absence of mesenchyme. These
results do not preclude an additional role for ROCK proteins possibly
expressed in mesenchymal cells.
ROCK I, expressed in the epithelium of developing SMGs, is the critical
ROCK isoform promoting SMG cleft progression
There are two ROCK isoforms, ROCK I (p160ROCK or ROKβ) and
ROCK II (ROKα) (Nakagawa et al., 1996), both of which are sensitive
to the ROCK inhibitors. To examine cell-type distribution of ROCK I
and II in mouse SMGs, we performed Western analysis on cell lysates
derived from the epithelium or mesenchyme (Fig. 2A). ROCK I, ROCK
II, and their downstream effector, MLC2, were expressed approxi-
mately two-fold higher in epithelial extracts than in mesenchymal
extracts. To conﬁrm the preferential expression of ROCK I and II in
the epithelium, we performed immunocytochemistry on intact E13
SMGs (Fig. 2B). In agreement with the Western analysis of cell
extracts, higher levels of both ROCK isoforms were detected in the
epithelium than in the mesenchyme. Interestingly, ROCK I showed
locally elevated regions of expression, whereas ROCK II was more
diffusely distributed, which is evident at high magniﬁcation (white
square, Fig. 2B).
ROCK I and ROCK II share 65% amino acid identity and some
functional overlap (Nakagawa et al., 1996). To determine if there is a
critical ROCK isoform(s) with a role in SMG branching, we treated
developing salivary glands with isoform-speciﬁc ROCK siRNAs.
Preferential uptake of siRNA in epithelial cells was observed, as
previously reported (Sakai et al., 2003) (Fig. S2). Knockdown of ROCK
I produced SMGmorphologies similar to those observed for the ROCK
inhibitors Y27632 and H-1152 (Fig. 2C, compare to Fig. 1A), whereas
there was little effect of ROCK II siRNA after 48 h. Morphometric
analysis indicated a signiﬁcant inhibition of branching with a dose-
dependent decrease in completed buds and an increase in initiated,
but not elongated, clefts with ROCK I siRNA knockdown but not with
ROCK II or control siRNA (white arrows, Fig. 2C). Furthermore, SMGs
treated with both ROCK I and II siRNAs in combination exhibited a
comparable fold change decrease in completed epithelial buds, and a
fold change increase in small initiated clefts as was observed for SMGs
cultured with ROCK I siRNA alone (Fig. 2C). Western blot analysis was
performed to assess the efﬁciency of ROCK I and II knockdown at the
protein level (Fig. 2D). Both ROCK I and II siRNAs resulted in
approximately 50% isoform-speciﬁc knockdown when used at a
400 nM concentration with non-targeting negative control siRNAs
having a minimal effect. Together, these results indicate that ROCK I is
the primary isoform involved in SMG branching morphogenesis and
further validates the use of pharmacological inhibitors as a means of
investigating the role of ROCK I during SMG branching.
ROCK I and myosin activity regulate cytoskeletal tension around the
periphery of epithelial buds
To determine if inhibition of myosin activity would likewise
affect cleft formation, we used the pharmacological inhibitor
blebbistatin, which prevents myosin function by locking myosin II
in its actin-detached state to prevent contractility (Kovacs et al.,
2004). Blebbistatin-treated E13 SMGs showed a similar morphology
to that of SMGs treated with Y27632, H-1152, or ROCK I siRNA (Fig.
3A, compare to Figs. 1A and 2C). Similarly, morphometric analysis
revealed a dose-dependent decrease in the number of newly
formed buds, and a corresponding increase in the number ofinitiated, but not elongated, clefts (white arrows, Fig. 3A), indicating
that myosin II, downstream of ROCK I, is a critical regulator of cleft
progression.
Since phosphorylation of MLC2 on Ser19 is required for its
activation, and this site is a target of ROCK (Amano et al., 1996;
Totsukawa et al., 2000), we investigated whether the treatment of
SMGs with Y27632, H-1152, and ROCK I siRNA caused a decrease in
phosphorylatedMLC2 (pMLC2). Both ROCK inhibitors as well as ROCK
I siRNA demonstrated a dose-dependent decrease in the amount of
pMLC2 (Ser19) relative to MLC2 (Fig. 3B). Immunocytochemistry
revealed that immunostaining for pMLC2 decreased when SMG
epithelial rudiments were treated with Y27632 or H-1152 (Fig. 3C
and data not shown), while myosin heavy chain IIb did not.
Signiﬁcantly, confocal stacks of SMGs in the Z dimension revealed
that pMLC2 was primarily localized to the periphery of epithelial
buds, while myosin IIb was present throughout. This peripheral
localization was substantially decreased when SMGs were cultured
with Y27632 or H-1152 (Fig. 3C and data not shown). Furthermore,
subpopulations of pMLC2 localized to both regions of the cytosol and
to patches along the plasma membrane, in a pattern similar to that of
both ROCK I and actin (Fig. 3D). Together, these data provide
molecular evidence that ROCK I functions upstream of myosin during
SMG branching morphogenesis to regulate actomyosin-based con-
tractility at the periphery of epithelial buds. Taken together with the
ﬁnding that the number of cleft initiation events at the epithelial
surface increases when contractility is inhibited (Figs. 1B, 2C, and 3A),
these data indicate that ROCK I may promote a steady state surface
tension that prevents multiple initiations from occurring within a
local area of the epithelial surface during normal development.
Given that ROCK I affects MLC2 activation, we expected to detect
morphological changes on the tissue level. We found that SMGs treated
for 24 h with Y27632, H-1152, or blebbistatin showed a signiﬁcantly
reduced thickness in the Z dimension relative to their vehicle control-
treated counterparts (Fig. 3E). Furthermore, morphometric analysis
revealed a corresponding increase in the diameter of SMGs treatedwith
the ROCK and myosin inhibitors relative to vehicle controls (Fig. 3E).
These changes in tissue morphology cannot be attributed to changes in
apoptosis (Fig. S1C, and data not shown). Together, these measure-
ments are indicative of a loss of cytoskeletal contractility at the tissue
level when ROCK I and myosin II are inhibited.
Inhibition of ROCK and myosin activity decreases SMG cell proliferation
We next questioned what mechanism might regulate the
transition of an initiated cleft to one competent for progression, as
well as the molecular and cellular basis for cleft progression itself.
Because recent studies suggest that enhanced cytoskeletal contractil-
ity can promote cell proliferation (Chen, 2008; Wozniak and Chen,
2009), we hypothesized that cell proliferation might be involved in
cleft progression despite previous reports that deny a role for
proliferation in SMG cleft initiation (Nakanishi et al., 1987). To this
end, we measured SMG cell proliferation at 24 h following a BrdU
pulse in the presence of vehicle control, Y27632, H-1152, or
blebbistatin. ROCK andmyosin-inhibited SMGs exhibited signiﬁcantly
decreased cell proliferation, as compared to their vehicle control-
treated counterparts (Figs. 4A and B and Fig. S3A), and with a
magnitude similar to that of hydroxyurea (HU), which blocks the cell
cycle in S phase by inhibiting ribonucleotide reductase (Karon and
Benedict, 1972) (Fig. S3A and C). Of note, these ﬁndings demonstrate
that the observed inhibitor-induced increase in SMG diameter (Fig.
3E) is not due to increased proliferation. Furthermore, these results
indicate that ROCK I and myosin II-mediated stimulation of prolifer-
ation may be involved in cleft formation.
Interestingly, we observed a large proportion of BrdU-positive
nuclei around the periphery of epithelial buds, in the outer basal
layer of epithelial cells in control SMGs. Because ROCK and myosin
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a consequent decrease in the number of proliferating cells in this
outer basal layer (Figs. S3B, compare white arrows). Since the
periphery of the bud is where clefts initiate, we hypothesized thatthis localized decrease in epithelial cell proliferation might contribute
to the failure in cleft progression that occurs when ROCK signaling is
perturbed. Examination of progressing clefts in vehicle control SMGs
revealed that BrdU-positive nuclei are present at the distal-most
Fig. 3.Myosin activity is required for SMG cleft progression and promotes cytoskeletal tension around the periphery of epithelial buds. (A) E13 SMGs cultured for 24 h with 100 μM
blebbistatin show an increased number of initiated, but not elongated, clefts (white arrows). Quantiﬁcation of morphological changes with increasing concentrations of blebbistatin.
(B)Western analysis reveals a dose-dependent decrease in the amount of phosphorylated pMLC2 in the presence of increasing concentrations of Y27632, H-1152, and ROCK I siRNA.
(C) Confocal images through the center of immunostained SMGs reveal that pMLC2 (green) is present around the periphery of epithelial buds (white arrows), while myosin IIb heavy
chain (red) is present throughout the epithelium in the Z dimension, shown as XY view (left) and XZ projection of a stack through the SMG (right). pMLC2 staining is decreased in
epithelial rudiments treated with 140 μM Y27632 for 24 h relative to vehicle control. (D) Confocal images show that ROCK I (cyan) is present at the epithelial surface with pMLC2
(green) and actin (red). (E) E13 SMGs cultured for 24 h with 140 μM Y27632, 2 μM H-1152, or 100 μM blebbistatin exhibit decreased thickness and expanded diameters relative to
vehicle control. ANOVA, ⁎pb0.05, ⁎⁎pb0.01. Scale bars, 250 μm (A), 20 μm (C), and 10 μm (D).
175W.P. Daley et al. / Developmental Biology 336 (2009) 169–182regions (Fig. 4A, arrows), but not in the proximal regions closer to
the cleft base (Fig. 4A, arrow heads). In contrast, these BrdU-positive
nuclei were absent in the presence of both ROCK and proliferation
inhibitors.
To further explore the relationship between ROCK-mediated
effects on proliferation and cleft formation, we performed morpho-
metric analysis on HU-treated SMGs and observed a dose-dependent
decrease in the number of completed epithelial buds when compared
with vehicle control-treated SMGs (Fig. 4C and Fig. S3D). Further-
more, while clefts initiated normally in the presence of HU, they failedFig. 2. ROCK I is expressed in the epithelium of E13 SMGs and regulates cleft progression. (A
that ROCK I, ROCK II, and MLC2 are expressed in both the epithelium and mesenchym
Immunocytochemistry of ROCK I (green) and ROCK II (cyan) demonstrates that both ROCK i
than in the mesenchyme. Confocal images were acquired from the center of each SMG. (C) Tr
nM ROCK II or negative control siRNA, reduces SMG branching with similar morphologi
incomplete clefts in ROCK I siRNA-treated SMGs but not control or ROCK II siRNA-treated S
ROCK I, but not ROCK II, blocks cleft progression and promotes additional initiation events. SM
and initiated clefts as SMGs treated with ROCK I siRNA alone. (D) Western blot analysis
Quantiﬁcation was normalized to GAPDH and expressed as a percentage relative to negativ
control siRNA. ANOVA, ⁎pb0.05, ⁎⁎pb0.01. Scale bars, 50 and 20 μm (B) and 250 and 50 μmto progress, similar to clefts in the presence of the ROCK and myosin
inhibitors (Fig. 4C, compare to Figs. 1B, 2C, and 3A). However, unlike
ROCK and myosin inhibitor treatments, which increase the number of
initiated clefts, HU-treated SMGs showed no signiﬁcant difference in
the number of initiated clefts relative to vehicle control (Fig. 4C).
These results suggest that ROCK- and myosin-mediated effects on the
number of initiated clefts are independent of cell proliferation.
However, since clefts in the HU-treated SMGs fail to progress, the
subsequent transition to progression-competent clefts appears to
require cell proliferation.) Western analysis of epithelial and mesenchymal cell extracts from E13 SMGs reveals
e, shown with quantiﬁcation of relative band intensity normalized to GAPDH. (B)
soforms are more highly expressed in the epithelium, demarked with E-cadherin (red),
ansfection of E13 SMGs for 48 h in organ culture with 400 nM ROCK I siRNA, but not 400
cal perturbations as the pharmacological ROCK inhibitors, High power images show
MGs (white arrows). Quantiﬁcation of siRNA-treated SMGs reveals that knockdown of
Gs treated with ROCK I and II siRNAs in combination exhibit similar fold changes in bud
to conﬁrm knockdown of ROCK I and ROCK II with isoform-speciﬁc ROCK siRNAs.
e control-treated SMGs. U, untreated; R, transfection reagent only; C, 400 nM negative
(C).
Fig. 4. Inhibition of ROCK and myosin activity decreases SMG proliferation. (A) Proliferation was assessed in E13 SMGs cultured for 24 h in the presence of 140 μM Y27632, 2 μMH-
1152, 100 μM blebbistatin, or 0.5 mM HUwith a BrdU assay: BrdU (proliferating nuclei, green), Na+/K+ ATPase (preferential for epithelial membranes, red). Proliferating nuclei are
localized at the distal ends of progressing clefts (white arrows) in vehicle control SMGs, but are absent from the proximal cleft base (arrow heads), apparent in confocal images. Such
BrdU-positive nuclei are greatly reduced with all inhibitor treatments. (B) Quantiﬁcation of proliferating nuclei expressed as BrdU-positive nuclei to total nuclei (SYBR green-
positive). (C) SMGs cultured for 24 h with 0.5 mM HU exhibit initiated but not progressing clefts, apparent at higher magniﬁcation (white arrows). Quantiﬁcation of the number of
completed buds and initiated clefts is shown for SMGs treated for 24 h with increasing concentrations of HU, in comparison with Y27632, H-1152, and blebbistatin. ANOVA,
⁎⁎pb0.01, N=5. Scale bars, 10 μm (A) and 250 μm (C).
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contribution
Since ROCK and myosin inhibitors both decrease cell proliferation
and contractility, we investigated the relative contribution of inward-
driven contractile forces versus outward-driven bud expansion forces
to cleft progression. We performed time-lapse imaging of SMGs
grown in the presence or absence of ROCK, myosin, or proliferation
inhibitors (Movie S2) and morphometric analysis on the cleft regions.
During cleft progression, the distance that the base of the cleft moved
inward was designated as the contractive index (CI). The expansion
index (EI) was established as a metric of the opposing end bud
outgrowth, and the progression index (PI) as a metric of cleft length
(see Fig. 5A for graphical depictions of the indices and Fig. S4A and B
for deﬁnition of the measurements and additional time-points,
respectively). Consistent with our previous ﬁndings, the PI was
signiﬁcantly decreased in all inhibitor-treated SMGs (Fig. 5C). In
vehicle control-treated SMGs, bud outgrowth progressed signiﬁcantly
away from the starting point, deﬁned as a positive EI, and the base of
the cleft progressed slightly inwards toward the interior of the bud,
deﬁned as a negative CI (Figs. 5B and C). Treatment of SMGs with HU
resulted in SMGs with signiﬁcantly reduced proliferation and a
coordinately reduced level of EI, but with a CI indistinguishable from
control (Figs. 5B and C). In contrast, when SMGs were treated withROCK ormyosin inhibitors, we observed a signiﬁcantly reduced EI, but
also a reversal of the CI into a net positive contribution, consistent
with a loss of cytoskeletal contractility at the surface of the bud.
Together, these ﬁndings lead us to conclude that cleft progression is
due primarily to a ROCK/myosin II-induced outgrowth of epithelial
cells in regions adjacent to the progressing cleft and to a lesser extent
from an inward-directed contractile force.
ROCK-mediated actomyosin contractility is required for the assembly of
ﬁbronectin (FN) into the basement membranes of branching SMGs
Thus far, we have demonstrated that cleft progression requires
both a contractive and proliferative contribution. We next sought to
determine the molecular mediators that integrate both of these
cellular processes. Previous studies have also demonstrated that the
ECM protein ﬁbronectin (FN) is required for cleft formation during
SMG branching morphogenesis (Sakai et al., 2003). Based on these
studies and others implicating ROCK-mediated actomyosin contrac-
tility in FN matrix assembly in ﬁbroblasts (Yoneda et al., 2007; Zhong
et al., 1998), we questioned whether the morphological perturbations
observed upon ROCK and myosin inhibition result from altered FN
dynamics during SMG development. Western analysis of E13 SMG cell
lysates treated for 24 h with vehicle control or ROCK and myosin
inhibitors showed no change in the amount of total endogenous FN
Fig. 5. Cleft progression requires both a proliferative and contractile contribution. (A) Schematic diagram of the expansion index (EI, cyan dotted line), representing epithelial
outgrowth, and the contractive index (CI, red dotted line), representing cleft base ingression, relative to a ﬁxed starting point (base of initiated cleft, black dotted line). The
progression index (PI) is a metric of cleft length. Measurements and calculations are detailed in Fig S4. (B) Montage of selected images from wideﬁeld time-lapse imaging of cleft
regions (see Movie S2) with the base of clefts (time 0, black dotted line), extent of bud outgrowth (ﬁnal time point, cyan line), and base of clefts (ﬁnal time point, red line) indicated
for control, 140 μM Y27632, 100 μM blebbistatin, and 0.5 mM HU-treated E13 SMG. (C) Quantiﬁcation of EI, CI, and PI (in AU). ANOVA ,⁎pb0.05, ⁎⁎pb0.01, N=6. Scale bar, 50 μm.
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change in the localization of FN within the basement membranes of
SMGs treated with ROCK or myosin inhibitors and ROCK I siRNA. As
shown in Fig. 6B, FN is present continuously throughout the entire
basement membrane of vehicle control-treated E13 SMGs, co-
localizing with the basement membrane proteins laminin-111 and
the heparan sulfate proteoglycan, perlecan (data not shown). In
contrast, SMGs cultured in the presence of Y27632, H-1152, or
blebbistatin exhibit disorganized FN within their basement mem-
branes, with areas lacking FN and other areas having punctate stitches
of FN (Fig. 6B, compare white arrows). Similarly, treatment of SMGs
with ROCK I siRNA also resulted in severe FN disorganization within
their basement membranes, with minimal effects associated with
negative control or ROCK II siRNAs (Fig. 6B). Signiﬁcantly, HU
treatment did not result in disorganized FN in the basement
membrane, as did the ROCK and myosin inhibitors (Fig. S5). These
results suggest that ROCK I-stimulated myosin activity is required for
localized FN assembly into the basement membrane of developing
SMGs, and that the FN disorganization observed in the basement
membranes of ROCK- and myosin-inhibited SMGs is not due to a
decrease in ROCK-stimulated cell proliferation.
Since cell surface-associated, unassembled FN is soluble in
deoxycholate (DOC), whereas fully extended, ﬁbrillar FN is not
(Sechler et al., 1996), we performed DOC extractions on ROCK- and
myosin-inhibited intact SMGs to detect levels of ﬁbrillar FN. Despite
the fact that large amounts of FN are produced by mesenchymal cells,
which may mask changes in FN assembly by the epithelium,
decreased levels of assembled, ﬁbrillar FN were detected in the DOC
insoluble fraction in the presence of the inhibitors relative to vehicle
control-treated samples (Fig. 6C).
To assess the effect of ROCK inhibition on FN assembly speciﬁcally
in salivary epithelial cells, we used the SCA-9 cell line (Barka et al.,2005; Barka et al., 1980). We determined that SCA-9 cells do assemble
a ﬁbrillar FN matrix, and that assembly of this matrix is disrupted
when either ROCK or myosin is inhibited (Fig. S6A), with FN primarily
localized within short stitches and punctate dots along the cell
periphery, reminiscent of FN localization within the basement
membranes of ROCK- and myosin-inhibited SMGs (Fig. 6B). To
determine if these punctate regions represent unassembled FN
bound to the cell surface, we performed time-lapse imaging of SCA-
9 cells cultured with ﬂuorescently labeled FN (Alexa647-FN) in the
presence or absence of ROCK and myosin inhibitors. We ﬁrst
conﬁrmed that Alexa647-FN was efﬁciently incorporated into pre-
existing FN ﬁbrils by comparing immunostainingwith endogenous FN
(Fig. S6B). We then examined FN matrix assembly in these cells using
time-lapse microscopy. We observed that Alexa647-FN was continu-
ously incorporated into a ﬁbrillar matrix over 18 h in vehicle control-
treated cells, but was evident only as cell surface-associated puncta in
ROCK- and myosin-inhibited cells (Fig. S6C).
Unfolding of dimeric FN molecules bound to cell surface integrin
receptors unmasks a cryptic self-association site enabling the self-
association of FN molecules to form a ﬁbrillar matrix (Zhang et al.,
1997; Zhong et al., 1998). The L8 monoclonal antibody binds to a site
within the I9 and III1 modules in FN that is only exposed when FN is
integrin-bound and stretched by cytoskeletal-mediated tension
(Chernousov et al., 1987; Zhong et al., 1998). We investigated
whether a reduction in actomyosin contractility was directly
responsible for the reduced FN matrix assembly observed in SCA-9
cells and salivary gland cultures. Inhibitor-treated SCA-9 cells were
incubated for 18 h with Alexa647-FN followed by immunostaining
with the L8 monoclonal antibody to label FN under tension and a total
anti-FN antibody to detect the entire FN matrix. For SCA-9 cells
treated with vehicle control alone, L8 recognized a FNmatrix that was
indistinguishable from that detected with both the polyclonal
Fig. 6. ROCK signaling is required for FN assembly in the basement membranes of branching SMGs. (A)Western analysis for FNwas performed on extracts of E13 SMGs treated for 24
hwith 140 μMY27632, 2 μMH-1152, or 100 μMblebbistatin. Quantiﬁcation of total endogenous FN, normalized to GAPDH and expressed relative to vehicle control, demonstrates no
signiﬁcant difference between treatments. (B) SMGs treated with Y27632, H-1152, blebbistatin, or ROCK I siRNA exhibit punctate, disorganized FN (green) in the basement
membrane surrounding epithelial buds (white arrows). E-cadherin (red) marks epithelial buds in confocal images acquired at the center of SMGs. (C) SMGs and SCA-9 cells treated
with Y27632, H-1152, or blebbistatin exhibit decreased DOC-insoluble FN relative to vehicle control. Quantiﬁcation of SMG and SCA-9 cell DOC extracts was normalized to vimentin
and GAPDH, respectively, and expressed relative to vehicle control. Vimentin (DOC insoluble) and actin (DOC soluble) conﬁrmed separation of the two fractions. (D)
Immunostaining of total exogenous FN matrices (green) by the L8 antibody (red) is decreased in SCA-9 cells treated with 50 μM Y27632 (white arrows), as observed with wideﬁeld
images. (E) Confocal images acquired from the center of E13 SMG epithelial rudiments treated with 140 μMY27632 show a reduction in L8 staining (red) of the basement membrane
around the periphery of epithelial buds relative to vehicle control-treated SMGs. ANOVA, *pb0.05, **pb0.01, N=3. Scale bars, 5 μm (B), 20 μm (D), and 20 and 10 μm (E).
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markedly decreased in cells cultured with Y27632, H-1152, or
blebbistatin (Fig 6D and Fig. S7B, compare white arrows). Similarresults were observed in E13 SMG epithelial rudiments, with L8
monoclonal antibody reactivity detected primarily within the base-
mentmembranes of vehicle control-treated rudiments, as determined
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incorporate into the epithelial basement membrane of E12 SMG
epithelial rudiments (Larsen et al., 2006) (Fig. 6E). In contrast, such
immunoreactivity is signiﬁcantly decreased in E13 rudiments cul-
tured in the presence of Y27632 (Fig. 6E), H-1152, or blebbistatin
(data not shown), instead exhibiting only remnant puncta of L8
staining. We conclude that ROCK I-mediated actomyosin contractility
is required for the stretching of cell surface-bound FN into an
assembly-competent state in salivary gland epithelial cells, and that
when either ROCK I or myosin activity is inhibited, FN ﬁbril assembly
is compromised.
Fibronectin promotes SMG epithelial cell proliferation and cleft
progression in a ROCK-dependent manner
We next questioned whether the defect in FN assembly into the
basement membranes of ROCK- and myosin-inhibited SMGs was
directly linked to the reduction in proliferation observed upon ROCKFig. 7. FN promotes epithelial cell proliferation in a ROCK-dependent manner. (A) Treatmen
branching morphogenesis. Such inhibition can be rescued by the addition of 0.5 mg/mL ex
Quantiﬁcation of the number of buds after 24 h in culture under the indicated conditions. (B)
h with BrdU. BrdU nuclei (cyan) are greatly reduced in the presence of 500 nM FN siRNA, wh
not in the presence of 140 μMY27632. E13 SMGs cultured for 24 h in the presence of increasin
in the presence of 140 μM Y27632. FN knockdown and incorporation were conﬁrmed by
Quantiﬁcation of BrdU-positive nuclei, expressed as a ratio to the total number of SYBR greenand myosin inhibition, and hence the lack of cleft progression. To this
end, we cultured E13 SMGs for 24 h in the presence of increasing
concentrations of FN siRNA, as previously reported for E12 SMGs
(Sakai et al., 2003). FN siRNA, but not a non-targeting negative
control siRNA, resulted in a dose-dependent inhibition of branching
due to a decrease in the number of cleft formation events, which
could be rescued by the addition of exogenous FN to the culture
medium (Fig. 7A and Fig. S8A). Interestingly, such rescue was
dependent upon ROCK activity, since the addition of Y27632 at the
same time as exogenous FN to FN siRNA-treated SMGs completely
abrogated this effect (Fig. 7A). We performed Western analysis on
SMG cell lysates treated with increasing concentrations of FN siRNA
to conﬁrm the efﬁciency of FN knockdown, and observed approxi-
mately 50% knockdown when siRNA was used at a 500 nM
concentration (Fig. S8B). Together, these results conﬁrm that FN
promotes cleft progression not only in E12 SMGs, as was previously
reported (Sakai et al., 2003), but also in E13 SMGs. Furthermore,
since the FN siRNA rescue requires ROCK activity, these resultst of E13 SMGs for 24 h with 500 nM FN siRNA, but not negative control siRNA, inhibits
ogenous plasma FN to the culture media, but not in the presence of 140 μM Y27632.
E13 SMGswere cultured for 24 h under the indicated culture conditions and pulsed for 2
ich can be rescued by the addition of 0.5 mg/mL exogenous FN to the culture media, but
g concentrations of exogenous FN exhibit increased incorporation of BrdU label, but not
staining for FN (green). Confocal images were acquired at the center of each SMG.
-positive nuclei. ANOVA, ⁎pb0.05, ⁎⁎pb0.01, N=5. Scale bars, 250 μm (A), 100 μm (B).
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just FN itself, that is speciﬁcally required for cleft progression.
We have demonstrated that cleft progression requires cell
proliferation. To assess the effect of FN knockdown on SMG cell
proliferation, E13 SMGs cultured for 24 h in the presence of FN siRNA
were subjected to a BrdU pulse. We observed a dose-dependent
decrease in the ratio of BrdU-positive to total nuclei with increasing
concentrations of FN siRNA, as conﬁrmed by co-staining for FN (Fig. 7B
and Fig. S8C). This defect in proliferation could be partially rescued by
the addition of exogenous FN to FN-siRNA-treated SMGs, but also
required ROCK activity, since FN siRNA-treated SMGs cultured with
both exogenous FN and Y27632 at the same time exhibited a level of
proliferation comparable to that of glands cultured with FN siRNA
alone (Fig. 7B). To determine whether FN alone was sufﬁcient to
promote SMG epithelial cell proliferation, we cultured intact E13
SMGs for 24 h with increasing concentrations of exogenous FN added
to the culture media. We observed a dose-dependent increase in the
ratio of BrdU-positive nuclei (Fig. 7B), as well as an increase in the
number of buds (Fig. S9A and B), both of which were also dependent
upon ROCK activity. SMGs treated with the same concentrations of
BSA did not show a change in BrdU-positive nuclei or in the number of
buds, thereby indicating that these changes are speciﬁcally caused by
FN. We conclude that ROCK I-mediated actomyosin contractility is
required for the assembly of FN into the basement membrane of
branching SMGs, which in turn stabilizes an initiated cleft to facilitate
its progression by enhancing localized epithelial cell proliferation. We
refer to the point at which a threshold of contractility is reached
within an initiated cleft to facilitate the transition to a progressing
cleft as a mechanochemical checkpoint.Discussion
The initial step of salivary gland branching morphogenesis is the
formation of clefts in the basement membrane surrounding a primary
epithelial bud. Following initiation, clefts progress, or extend, to a
certain point before terminating, and the process begins anew. Prior
to this study, it was unclear if cleft progression was a continuation of
cleft initiation or a separate event. Here, we describe a crucial role for
ROCK I-mediated signaling through its downstream effector MLC2 in
the differential regulation of both cleft initiation and progression
during SMG branching morphogenesis. Our data support a role for
ROCK I/myosin II-mediated contractility in regulating a checkpoint
facilitating the transition of initiated clefts to a progression-compe-
tent state. Once a cleft passes through this checkpoint, the major
contributor to cleft progression is cell proliferation with a contractile
component. Our data also support a role for ROCK I/myosin II in a
negative feedback loop that maintains the basement membrane in aFig. 8. Proposed model for ROCK I-mediated actomyosin contractility during SMG cleft form
transition to a progression-competent, stabilized cleft, requiring localized contractility-media
outward-directed expansion force that overcomes surface tension resulting in cleft progress
temporarily preventing initiation of additional clefts.contracted state that is not immediately competent to initiate
additional clefts (Fig. 8).
We propose a model for cleft progression in which a localized
increase in ROCK I-mediated actomyosin contractility reaches a
certain threshold that triggers the assembly of FN ﬁbrils in the cleft
region, which in turn promotes epithelial cell proliferation in the
regions adjacent to the stabilized cleft. The outward-directed force
generated by such proliferative outgrowth would overcome the
steady state surface tension at the periphery of epithelial buds, thus
resulting in cleft progression (Fig. 8). Our results indicate that
proliferation is not required for cleft initiation, which is in agreement
with a previous report (Nakanishi et al., 1987), but demonstrate that
progression of initiated clefts does depend upon cell proliferation.
The decrease in proliferation that we observed upon treatment of
SMGs with FN siRNA and blebbistatin suggests that the proliferative
effects of ROCK I signaling are primarily mediated through FN. Indeed,
it has recently been shown that FN enhances proliferation in a
mammary epithelial 3D cell culture model (Williams et al., 2008) and
that cardiacmyocyte proliferation is regulated in part by FN binding to
β1 integrins (Ieda et al., 2009). However, we cannot rule out the
possibility that to some degree ROCK I can promote SMG cell
proliferation independently of FN and independent of myosin.
Interestingly, a recent study demonstrated that signaling through
ROCK modulates the G1/S transition by many mechanisms in mouse
NIH 3T3 ﬁbroblasts, some requiring ROCK-mediated effects on the
actin cytoskeleton and others not (Croft and Olson, 2006). Since
growth factor-dependent pathways signal through ERK1/2 to
promote proliferation in branching SMGs (Kashimata et al., 2000;
Steinberg et al., 2005), and a contracted actin cytoskeleton is
implicated in the maintenance of robust MAPK signaling (Croft and
Olson, 2006;Welsh et al., 2001), cross-talk may exist between growth
factor and ROCK I-stimulated proliferation in branching SMGs.
We identiﬁed FN assembly as a crucial downstream effect of ROCK
I/myosin II signaling in cleft progression. Previous studies demon-
strated a requirement for FN and its receptor integrin α5β1 in the
process of SMG cleft formation (Sakai et al., 2003) and inward-
directed FN assembly in progressing clefts (Larsen et al., 2006), yet
signals regulating FN assembly were not identiﬁed. Here, we
demonstrate that signaling through ROCK I and myosin II drives
organized FN matrix assembly in branching SMGs. These results, in
combination with the previously demonstrated involvement of FN in
cleft formation (Larsen et al., 2006; Sakai et al., 2003), are consistent
with a requirement for FN assembly in the basement membrane to
stabilize clefts, rendering them competent for progression. We
propose that such stabilization is required for passage through a
mechanochemical checkpoint that senses the contractile state of the
basement membrane at the initiated cleft to facilitate the transition of
initiated clefts into a progression-competent state. Although theation. ROCK I signaling regulates a checkpoint by which an initiated cleft undergoes a
ted FN assembly. FN promotes localized epithelial cell proliferation, which generates an
ion, ROCK I-mediated actomyosin contractility also stimulates a negative feedback loop,
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requires inside-out integrin signaling.
Our results are consistent with other studies showing that ROCK-
mediated actomyosin contractility promotes the unfolding of cell
surface-bound FN in 2D cell cultures to expose a cryptic self-
association site that enhances its assembly into a ﬁbrillar matrix
(Baneyx et al., 2002; Yoneda et al., 2007; Zhong et al., 1998). We
detect a decreased amount of FN in the DOC insoluble fraction of
ROCK- and myosin-inhibited SMGs, although this decrease is much
more obvious in our 2D cell culture experiments with SCA-9 cells. This
is not altogether surprising, given that DOC insoluble FN has recently
been reported to be difﬁcult to detect in in vivo Xenopus extracts
(Dzamba et al., 2009). Taken together with our results with the L8
monoclonal antibody, however, we conclude that ROCK I-mediated
actomyosin contractility is an important determinant of FN assembly
in branching SMGs, primarily due to its ability to promote the
extension of FN into an assembly-competent state. Interestingly, in
embryonic lung, the blockade of ROCK signaling with Y27632 also
inhibits branching. Such effects were suggested to be a result of
defects in the actomyosin-dependent contraction of the basement
membrane, and a consequent loss of localized differentials in
basement membrane remodeling and epithelial cell proliferation
(Moore et al., 2005). While FN is also required for branching in the
lung (De Langhe et al., 2005; Sakai et al., 2003), a role for ROCK in this
mechanism was not investigated. Furthermore, no direct links were
established between basement membrane remodeling and localized
cell proliferation. This is the ﬁrst report to demonstrate that ROCK/
myosin II signaling regulates FN assembly within the basement
membrane in cleft formation during branching morphogenesis, and
that FN itself speciﬁcally induces epithelial cell proliferation to
stimulate cleft progression.
Interestingly, we identiﬁed unexpected roles for ROCK I/myosin II-
mediated signaling in cleft initiation. The observed decrease in
proliferation of the subset of proliferating cells localized to distal
cleft regions when ROCK I or myosin activity was inhibited correlated
with incomplete clefts failing to progress. However, this decreased
proliferation did not account for the increased numbers of these small
initiated clefts in the surface of the epitheliumwhen ROCK I or myosin
was inhibited, since treatment with HU did not signiﬁcantly increase
the number of such clefts. This indicates that cleft initiation events
relate to ROCK I/myosin II-mediated changes in cellular contractility.
Our results are compatible with a model in which decreased
contraction in the presence of ROCK I ormyosin inhibitors destabilizes
the basement membrane, allowing additional cleft initiations in a
proliferation-independent manner during normal development. We
propose that ROCK I-mediated actomyosin contractility at the bud
periphery constitutes a negative feedback loop that locally maintains
the basement membrane in a contracted state until completion of the
currently progressing cleft, thus preventing further cleft initiations.
Indeed, such an occurrence would not be without precedence, since a
recent study by Fischer et al. in a 3D model of endothelial cell
branching morphogenesis identiﬁed ROCK-mediated myosin II acti-
vation and the resulting cortical tension as a negative regulator of
pseudopodial branch initiation (Fischer et al., 2009).
A general assumption regarding regulation of branching morpho-
genesis has been that the primary point of regulation is cleft initiation
itself, with a possible initiating signal of mesenchymal origin. In fact,
the mechanism of cleft initiation remains unknown although putative
initiator proteins have been identiﬁed, one of which is a class 3
semaphorin (Chung et al., 2007). However, our results presented here
suggest that instead of a pre-determined cleft initiation site regulated
by an initiator signal, the entire epithelial surface may be competent
to undergo cleft initiation events, and that the primary point of
regulation may be the checkpoint prior to cleft progression. This
modelmay explainwhy epithelial tissue can undergo branching in the
absence of mesenchyme.The effect of ROCK signaling in other branching organs is reported
to differ from what we report here. In the lung, ROCK signaling
positively regulates epithelial branching (Moore et al., 2005), while in
the embryonic kidney, ROCK was reported to be a negative regulator
of this process (Korostylev et al., 2008; Meyer et al., 2006). However,
upon closer examination, some similarities between the proposed
mechanisms of ROCK signaling in these different systems are
apparent. We here identiﬁed a role for ROCK in FN assembly in the
basement membrane during cleft progression, whereas in lung, a
ROCK-dependent change in basement membrane thickness was
reported (Moore et al., 2005). When isolated ureteric buds are treated
with ROCK inhibitors, they exhibit very small buds that do not
elongate ductal structures (Meyer et al., 2006), suggesting a role for
ROCK signaling in an analogous cleft progression checkpoint during
kidneymorphogenesis. Further studies will be required to understand
speciﬁc similarities and differences in ROCK-stimulated signaling
during branching morphogenesis.
In conclusion, we report evidence for a ROCK I/myosin II-controlled
checkpoint regulating the transition of clefts from initiation to
progression. Lack of cleft progression is associated with decreased
cytoskeletal contractility, decreased FN assembly, and subsequent
decreased proliferation. Additionally, in the presence of ROCK I/myosin
II inhibition, additional cleft initiation events occur in a proliferation-
independent manner due to a loss in contractility in the basement
membrane at the periphery of epithelial buds. Our data indicate that
cleft initiation and progression are, in fact, two distinct morphological
events during SMG branching and that a checkpoint regulates the
transition from one to the other. To the best of our knowledge, this is
theﬁrst published report describing a checkpoint regulating the process
of branching morphogenesis.Acknowledgments
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